Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Getting the Word Out, For Once | Main | A Birthday Worth Noting »

March 25, 2004

Tasty New Recipes for the Root of All Evil

Email This Entry

Posted by Derek

A couple of items from the business and economic side of things: First off, Daniel Gross over at Slate's Moneybox column has an excellent take on the stupidity of the French government's meddling in the Aventis takeover. Novartis has been producing bid-making noises, but says that the French government has to get out of the picture for it to consider getting involved. Says Gross:


"What the French and German governments are really doing here is erecting artificial obstacles to a deal. These barriers to foreign bidders drain the pool of potential buyers and hence suppress asset prices-ultimately making the target firms weaker and poorer."

Exactly right. The same kind of argument can be made against all sorts of other protectionist schemes. And no, reimporting pharmaceuticals at an artificially low fixed price does not count as free trade in my book. Free trade is when everyone markets their goods wherever they want to, charging whatever price they believe that the market will bear. We should give it a try sometime, and that goes for drugs, for wheat, for shoes and sugar and silk. The lot. That it should apply to the buying and selling of companies should be obvious, but not, it seems, in Europe.

The other thing that caught my attention was a headline in the New York Times. "Drug Company with No Products Raises 250 Million." Sounds good to me! Many of us work at companies with almost no products - does that count? Can we get, say, two hundred million on the same principle?

The company in question is Jazz Pharmaceuticals, founded by some ex-Alza folks. Mighty strange name for a drug company, guys. They're going to develop CNS drugs, but they're not going to discover any of them. All of them will be in-licensed. Now, this business plan is not insane on the face of it. The idea of a "virtual drug company" has been floating around for some years, and occasionally it comes in for a landing. Such an outfit would be, essentially, a regulatory and marketing services company, for research organizations unwilling or unable to do those tasks themselves.

But neuropsychiatric drugs are notoriously tricky. Their developmental paths are long, expensive, and have many exciting plot twists. If I were going to be an in-licensing firm, I don't think this is the street I'd choose to hang out my shingle. But hey, I drive a car that I bought before the Berlin Wall came down. These Bebop folks are the ones who just set a record for second-round financing. Good luck to 'em.

Comments (0) | Category: Business and Markets


COMMENTS

EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Molecular Printing of Drug Molecules. Say What?
Pfizer Walks Again By Night
Gitcher SF5 Groups Right Here
Changing A Broken Science System
One and Done
The Latest Protein-Protein Compounds
Professor Fukuyama's Solvent Peaks
Novartis Gets Out of RNAi